Zevra Therapeutics, Inc. (NASDAQ: $ZVRA) reported second-quarter 2026 revenue of $39.7 million, up 53.3% from a year earlier and ahead of the $34.6 million analyst estimate. Gross profit rose sharply to $41.2 million, reflecting stronger top-line performance.
Profitability was more mixed. Operating profit came in at $16.8 million, while net income attributable to common shareholders was $8.8 million, with diluted earnings per share of $0.14. That still topped the $0.11 earnings estimate.
The company also ended the quarter with a stronger balance sheet, holding $145.3 million in cash and cash equivalents, up significantly from the prior year. Total liabilities declined to $85.1 million, while operating cash flow remained positive at $17.0 million.
- Revenue: $39.7 million
- Gross profit: $41.2 million
- Diluted EPS: $0.14
- Cash and cash equivalents: $145.3 million
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
Zevra Therapeutics, Inc. Insider Trading Activity
Zevra Therapeutics, Inc. insiders have traded $ZVRA stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $ZVRA stock by insiders over the last 6 months:
- RAHSAAN THOMPSON (Chief Legal & Compliance) has made 0 purchases and 2 sales selling 36,351 shares for an estimated $458,575.
- NEIL F. MCFARLANE (President and CEO) sold 14,625 shares for an estimated $125,185
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Zevra Therapeutics, Inc. Hedge Fund Activity
We have seen 60 institutional investors add shares of Zevra Therapeutics, Inc. stock to their portfolio, and 71 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 2,025,000 shares (-91.0%) from their portfolio in Q1 2026, for an estimated $18,873,000
- AIGH CAPITAL MANAGEMENT LLC added 1,200,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $11,184,000
- POINT72 ASSET MANAGEMENT, L.P. added 1,157,131 shares (+inf%) to their portfolio in Q1 2026, for an estimated $10,784,460
- FMR LLC added 818,384 shares (+34.2%) to their portfolio in Q1 2026, for an estimated $7,627,338
- NANTAHALA CAPITAL MANAGEMENT, LLC added 750,000 shares (+42.3%) to their portfolio in Q1 2026, for an estimated $6,990,000
- MILLENNIUM MANAGEMENT LLC removed 544,089 shares (-48.0%) from their portfolio in Q1 2026, for an estimated $5,070,909
- QUBE RESEARCH & TECHNOLOGIES LTD added 486,076 shares (+136.4%) to their portfolio in Q1 2026, for an estimated $4,530,228
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Zevra Therapeutics, Inc. Price Targets
Multiple analysts have issued price targets for $ZVRA recently. We have seen 7 analysts offer price targets for $ZVRA in the last 6 months, with a median target of $29.0.
Here are some recent targets:
- Brandon Folkes from HC Wainwright & Co. set a target price of $26.0 on 06/23/2026
- Sumant Kulkarni from Canaccord Genuity set a target price of $29.0 on 06/11/2026
- Eddie Hickman from Guggenheim set a target price of $29.0 on 06/10/2026
- Jason McCarthy from Maxim Group set a target price of $35.0 on 06/10/2026
- Jason Butler from Citizens set a target price of $25.0 on 06/09/2026
- Kambiz Yazdi from BTIG set a target price of $27.0 on 06/09/2026
- Kristen Kluska from Cantor Fitzgerald set a target price of $34.0 on 06/08/2026
